Market protection for biotech drugs should be less than 12 years

11/24/2009 | Boston Globe (tiered subscription model), The

Giving 12 years of market protection to brand-name biopharmaceuticals would add to mounting pressure on health care costs and deprive patients of affordable follow-on biologics for many years, according to this editorial in The Boston Globe. Congress should enact a law that provides exclusivity for more than five years but fewer than 12 to balance innovation and affordability of biotech drugs, the editorial board writes.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX